Natera Wolfe Research Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
All right, great. Let's get started. Hi, everyone. Thanks for being here. My name is Paige Chamberlain. I lead the specialty diagnostics effort here at Wolfe Research. I am pleased to be joined in this session by Natera. We have CFO Mike Brophy with us. Mike, thank you for being here.
Hey, thanks for having me.
Mike, I got to say, you gave me a lot of material to work with last week, so thank you for that.
Henry and the vultures, is that what you were going to come back with?
Yeah, that's where I was going to start.
Yeah. Actually, I'll lay out the roadmap.
Yeah. I say we start with some updates out of last week, and then maybe hit on Signatera a few different ways, and then round out with screening, if that's okay with you.
So, you have a new CEO- Yeah effective immediately.
Yeah. Tell me about Solomon.
Yeah. Solomon was circa the 40th employee that joined the company back in 2011. I think as he mentioned on the call, he shared an office with Steve when Steve first hired him, when this was just an IVF company back in the day. He has led almost every different area of the business since then, from women's health marketing to key pieces of the product and development team. He's probably the one person that's most responsible in the company for the existence of, for example, Prospera. It was really his insight and initiative to make the connection between the NIPT assay and the unmet need that transplant recipients were facing. He had a preexisting collaboration with a key opinion leader in the transplant space at UCSF.
He was able to help to productize a version, an early version of Prospera, get the clinical trial enrolled, and get the readout. That was an enormous kind of next step for the company. In Signatera, he was the original general manager for Signatera. He was absolutely fundamental in the core decisions around how the product would be designed, what type of clinical trials would we run, what types of clinical questions would we answer with Signatera. So, he's been absolutely fundamental to the business in its longer history. More recently, he's served as the president of clinical genomics, and he's been a member of our four-person operating committee. So he's had broad oversight over execution generally in the business. For example, I interact with him all the time, even on things as seemingly distant from his responsibilities as the guide, right?
When we make a decision like how to guide for the year, Solomon's always been involved in that conversation. Everyone knows him. He's deeply steeped in the business. He's absolutely well-positioned to lead us from here.
I think I hear in all of that, like, the why Solomon answer.
Yeah. Why the transition, yeah.
Maybe why now? Could you help us with that one?
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
